Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (PAVM) is a commercial-stage medical technology leader driving innovation in diagnostic testing, medical devices, and digital health solutions. This dedicated news hub provides investors and industry professionals with timely updates on corporate developments, clinical milestones, and strategic initiatives shaping the future of preventive care technologies.
Access official press releases, earnings reports, and regulatory filings in one centralized location. Our curated collection features updates on product commercialization progress, FDA clearances, and partnership announcements, enabling stakeholders to track the company’s execution of its rapid concept-to-market strategy across multiple healthcare sectors.
Key content categories include financial performance updates, new product launches, clinical study results, and executive leadership developments. The resource is particularly valuable for monitoring advancements in PAVmed’s flagship diagnostic tools like the EsoGuard test and digital health platforms through subsidiary Veris Health.
Bookmark this page for streamlined access to verified information directly from corporate communications. Check regularly for updates on PAVmed’s progress in commercializing technologies designed to improve early disease detection and patient care delivery.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has appointed Gary Manning as the President of its majority-owned subsidiary, Veris Health. Manning brings over 30 years of digital health and medical technology experience, which includes expertise in developing innovative solutions for patient care. His role will focus on driving the commercialization of the Veris Cancer Care Platform™ and guiding product development and regulatory milestones for an implantable cardiac monitor. Chairman and CEO Lishan Aklog expressed confidence in Manning's ability to enhance Veris’s strategic direction. The Veris Cancer Care Platform enables remote monitoring of cancer patients, integrating Bluetooth-enabled devices to transmit health data. This appointment is anticipated to strengthen Veris's market position in personalized cancer care.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) presented a meta-analysis on Remote Patient Monitoring (RPM) at the HIMSS23 Global Health Conference on April 19, 2023. This analysis, titled "RPM for Oncology: Bringing the Hospital Home to Improve Lives," highlights RPM's potential to enhance quality of care, reduce healthcare costs, and improve patient experiences. The meta-analysis reviewed nearly two decades of oncology research from over ten countries, emphasizing the integration of RPM with patient-reported outcomes (ePROs) for personalized cancer care. PAVmed's digital health subsidiary, Veris Health, showcased its Veris Cancer Care Platform™ during the session, which enables remote monitoring and real-time data transmission to improve patient management.
FAQ
What is the current stock price of Pavmed (PAVM)?
What is the market cap of Pavmed (PAVM)?
